A universal cyclin-dependent kinase inhibitor and the primary transcriptional effector through which the p53 tumor suppressor halts the cell cycle in response to DNA damage. Simultaneously identified in 1993 by Wafik El-Deiry, Bert Vogelstein, and colleagues as WAF1 (Wild-type p53-Activated Fragment 1) and by J. Wade Harper, Stephen Elledge, and colleagues as CIP1 (CDK-Interacting Protein 1), p21 inhibits G1/S cyclin–CDK complexes and directly binds proliferating cell nuclear antigen (PCNA) to pause DNA replication while repair proceeds.
Human p21 is an intrinsically disordered 164-residue polypeptide that adopts a rigid folded conformation only upon engaging its target protein complexes.
Its N-terminal region contains distinct cyclin-binding (Cy1) and kinase-binding motifs that span both subunits of a cyclin–CDK heterodimer, while its C-terminal domain contains a nuclear localization signal and a high-affinity PIP-box motif that docks onto the homotrimeric PCNA sliding clamp.
Function
Unlike p16INK4a, which selectively targets monomeric CDK4 and CDK6, p21 binds intact Cyclin E/CDK2 and Cyclin A/CDK2 complexes (and at high stoichiometry inhibits Cyclin D/CDK4/6), inserting a 3₁₀ helix into the CDK catalytic cleft to block ATP binding and substrate phosphorylation. By preventing CDK2 from phosphorylating Rb (encoded by RB1), p21 blocks E2F-driven transcription and enforces the G1/S checkpoint; simultaneously, its C-terminal PIP-box competes with replicative DNA polymerases δ and ε for PCNA binding without blocking DNA ligase-associated excision repair.
Regulation
When double-strand breaks — whether from ionizing radiation, replication stress, or CRISPR-Cas9 cleavage — activate the p53/MDM2 DNA-damage response, tetrameric p53 (encoded by TP53) binds response elements in the CDKN1A promoter to drive a rapid surge in p21 mRNA transcription.
Also induced via p53-independent pathways by TGF-β / SMAD4 signaling and vitamin D receptor (VDR) activation during terminal cellular differentiation, and repressed post-transcriptionally by oncogenic microRNAs such as miR-106b and miR-17.
Interactions
Senescence relay: During the initiation of cellular senescence, p21 establishes the early, reversible cell-cycle pause before rising p16INK4a levels lock in permanent arrest.
Compartment switch: Phosphorylation of p21 at Thr145 by Akt (PI3K/AKT signaling) retains p21 in the cytoplasm, where it inhibits procaspase-3 and ASK1/JNK apoptotic cascades.
Clinical Relevance
Unlike TP53 or CDKN2A, somatic loss-of-function mutations in CDKN1A are rare in human tumors; instead, loss of upstream p53 silences DNA-damage-induced p21 expression, whereas cytoplasmic p21 accumulation in cancers confers resistance to cytotoxic chemotherapy.
In CRISPR-Cas9 genome editing of primary stem cells, Cas9-induced double-strand breaks trigger a p53–p21 arrest that selects against edited cells unless transiently modulated.